Pharmacokinetic variability of extended interval tobramycin in burn patients.

BACKGROUND Aminoglycosides are mandatory in the treatment of severe infections in burns. However, their pharmacokinetics are difficult to predict in critically ill patients. Our objective was to describe the pharmacokinetic parameters of high doses of tobramycin administered at extended intervals in severely burned patients. METHODS We prospectively enrolled 23 burned patients receiving tobramycin in combination therapy for Pseudomonas species infections in a burn ICU over 2 years in a therapeutic drug monitoring program. Trough and post peak tobramycin levels were measured to adjust drug dosage. Pharmacokinetic parameters were derived from two points first order kinetics. RESULTS Tobramycin peak concentration was 7.4 (3.1-19.6)microg/ml and Cmax/MIC ratio 14.8 (2.8-39.2). Half-life was 6.9 (range 1.8-24.6)h with a distribution volume of 0.4 (0.2-1.0)l/kg. Clearance was 35 (14-121)ml/min and was weakly but significantly correlated with creatinine clearance. CONCLUSION Tobramycin had a normal clearance, but an increased volume of distribution and a prolonged half-life in burned patients. However, the pharmacokinetic parameters of tobramycin are highly variable in burned patients. These data support extended interval administration and strongly suggest that aminoglycosides should only be used within a structured pharmacokinetic monitoring program.

[1]  M E Burton,et al.  A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration , 1991, Clinical pharmacology and therapeutics.

[2]  P. Doyle,et al.  Comparative analysis of two rapid, automated methods for determining aminoglycoside levels , 1984, Journal of clinical microbiology.

[3]  M. Tod,et al.  Individualising Aminoglycoside Dosage Regimens after Therapeutic Drug Monitoring , 2001, Clinical pharmacokinetics.

[4]  A. Cercós-Lletí,et al.  Pharmacokinetic Model for Tobramycin in Acinetobacter Meningitis , 2002, The Annals of pharmacotherapy.

[5]  Jay P. Sanford.  The Sanford Guide to Antimicrobial Therapy , 2000 .

[6]  J. Borrás-Blasco,et al.  Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation , 2004, Journal of clinical pharmacy and therapeutics.

[7]  H Birn,et al.  Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. , 2000, The Journal of clinical investigation.

[8]  D. Bailey,et al.  Gentamicin and tobramycin binding to human serum in vitro. , 2004, Journal of analytical toxicology.

[9]  H. Bruining,et al.  Experience with a once-daily dosing program of aminoglycosides in critically ill patients , 2002, Intensive Care Medicine.

[10]  J. Turnidge.  Pharmacodynamics and dosing of aminoglycosides. , 2003, Infectious disease clinics of North America.

[11]  G. Houin,et al.  Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. , 2006, International journal of antimicrobial agents.

[12]  T. Dorman,et al.  Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. , 1998, Surgery.

[13]  M. Takano,et al.  Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. , 2004, Drug metabolism and pharmacokinetics.

[14]  M. Weinbren.  Pharmacokinetics of antibiotics in burn patients. , 1999, The Journal of antimicrobial chemotherapy.

[15]  J. Rotschafer,et al.  Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. , 1997, The Journal of burn care & rehabilitation.

[16]  B. Erstad,et al.  Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. , 2000, The Journal of trauma.